Wyndham Hotels & Resorts, Inc.
WH · NYSE
Analyst ratings
buy · 10 ratings
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| July 17, 2026 | Morgan Stanley | Maintains | Overweight | $93.00 |
| July 16, 2026 | Wells Fargo | Maintains | Equal-Weight | $98.00 |
| May 12, 2026 | Morgan Stanley | Maintains | Overweight | $89.00 |
| May 4, 2026 | Susquehanna | Maintains | Neutral | $90.00 |
| April 23, 2026 | Susquehanna | Maintains | Neutral | $95.00 |
| April 21, 2026 | JP Morgan | Maintains | Overweight | $100.00 |
| April 16, 2026 | Barclays | Maintains | Overweight | $104.00 |
| April 10, 2026 | Morgan Stanley | Maintains | Overweight | $87.00 |
| March 26, 2026 | Truist Securities | Maintains | Buy | $107.00 |
| March 10, 2026 | Morgan Stanley | Maintains | Overweight | $85.00 |
| February 20, 2026 | Mizuho | Maintains | Outperform | $108.00 |
| February 3, 2026 | JP Morgan | Maintains | Overweight | $91.00 |
| February 3, 2026 | Truist Securities | Maintains | Buy | $99.00 |
| January 28, 2026 | Stifel | Maintains | Buy | $93.00 |
| January 16, 2026 | Morgan Stanley | Maintains | Overweight | $89.00 |
| January 16, 2026 | Barclays | Maintains | Overweight | $93.00 |
| January 13, 2026 | Mizuho | Upgrades | Outperform | $97.00 |
| December 17, 2025 | Barclays | Maintains | Overweight | $94.00 |
| December 15, 2025 | Goldman Sachs | Downgrades | Neutral | $76.00 |
| October 28, 2025 | Baird | Maintains | Outperform | $89.00 |
| October 27, 2025 | Susquehanna | Maintains | Neutral | $80.00 |
| October 24, 2025 | Barclays | Maintains | Overweight | $95.00 |
| October 23, 2025 | Stifel | Maintains | Buy | $95.50 |
| October 3, 2025 | Barclays | Maintains | Overweight | $99.00 |
RevPAR resilience and demand outlook amid macroeconomic uncertainty
Wyndham posted better-than-expected Q1 2026 results with EPS of $0.96 versus the $0.85 estimate, and management set confident FY 2026 guidance of $4.62–$4.80 EPS. Record travel demand, including a record number of Americans expected to travel over the July 4th holiday, supports continued RevPAR strength.
Analysts have downgraded Wyndham to Hold citing a worsened demand backdrop, with concerns that sustained RevPAR softness could interact negatively with the company's cost structure. Significant U.S. exposure also creates vulnerability to demand shocks from geopolitical tensions and reduced inbound travel.
Balance sheet leverage and capital allocation strategy
Wyndham's asset-light franchise model generates steady fee-based revenue, supporting ongoing share buybacks and a $1.72 annualized dividend. Deutsche Bank and Barclays both maintain buy or overweight ratings, with price targets of $105 and $104 respectively, reflecting confidence in the company's financial flexibility.
The issuance of $650 million in Senior Notes due 2033, combined with active buybacks and dividends, raises concerns about rising leverage and refinancing risk. Options market implied volatility signals that investors are increasingly uncertain about Wyndham's capacity to sustain growth investments while managing its debt load.
Long-term room growth and pipeline execution in key markets
Wyndham's development pipeline has reached a record 255,000 rooms, with management targeting 4% to 4.6% net room growth. The company projects $1.7 billion in revenue and $446.2 million in earnings by 2029, reflecting a 5.7% annual revenue growth trajectory supported by global franchising expansion.
A strategic shift in China introduces execution risk, as that market has historically been a key growth driver. Some analysts estimate Wyndham's fair value at roughly 10% below current trading levels, questioning whether the pipeline can be converted to revenue fast enough to justify current valuations amid uncertain global travel conditions.